Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Zanger

Showing results (121-130 of 203) with videos related to

Pageof 21
Sort By:
Pharmacogenomics|June 15, 2007
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitroZeruesenay Desta, Tanja Saussele, Bryan Ward, et al.
Pharmacogenetics|August 1, 1997
Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancerK T Kivistö, E U Griese, T Stüven, et al.
Pharmacogenetics and Genomics|September 27, 2006
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing eventsClaudia Toscano, Kathrin Klein, Julia Blievernicht, et al.
Pharmacogenomics|September 13, 2013
ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expressionTarek Magdy, Rudolf Arlanov, Stefan Winter, et al.
Clinical Pharmacology and Therapeutics|October 2, 2009
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivoS Riedmaier, K Klein, U Hofmann, et al.
Clinical Pharmacology and Therapeutics|November 8, 2013
Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymesU M Zanger, K Klein, M Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesWerner Schroth, Lydia Antoniadou, Peter Fritz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 14, 2018
Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG CellsNorman Tanner, Lisa Kubik, Claudia Luckert, et al.
Pharmacogenetics and Genomics|November 8, 2005
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenzKathrin Klein, Thomas Lang, Tanja Saussele, et al.
Pharmacogenetics|July 27, 2001
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liverT Lang, K Klein, J Fischer, et al.
Pageof 21

Showing results (121-130 of 203) with videos related to

Sort By:
Pageof 21
Pharmacogenomics|June 15, 2007
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitroZeruesenay Desta, Tanja Saussele, Bryan Ward, et al.
Pharmacogenetics|August 1, 1997
Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancerK T Kivistö, E U Griese, T Stüven, et al.
Pharmacogenetics and Genomics|September 27, 2006
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing eventsClaudia Toscano, Kathrin Klein, Julia Blievernicht, et al.
Pharmacogenomics|September 13, 2013
ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expressionTarek Magdy, Rudolf Arlanov, Stefan Winter, et al.
Clinical Pharmacology and Therapeutics|October 2, 2009
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivoS Riedmaier, K Klein, U Hofmann, et al.
Clinical Pharmacology and Therapeutics|November 8, 2013
Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymesU M Zanger, K Klein, M Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesWerner Schroth, Lydia Antoniadou, Peter Fritz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 14, 2018
Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG CellsNorman Tanner, Lisa Kubik, Claudia Luckert, et al.
Pharmacogenetics and Genomics|November 8, 2005
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenzKathrin Klein, Thomas Lang, Tanja Saussele, et al.
Pharmacogenetics|July 27, 2001
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liverT Lang, K Klein, J Fischer, et al.
Pageof 21